A Phase 1/2 Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combination With Pembrolizumab (KEYTRUDA) in Patients With Relapsed or Refractory Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 01 Sep 2017
At a glance
- Drugs Birinapant (Primary) ; Pembrolizumab
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Medivir AB; TetraLogic Pharmaceuticals
- 29 Aug 2017 Planned End Date changed from 1 Mar 2021 to 1 Jun 2021.
- 29 Aug 2017 Planned primary completion date changed from 1 Jan 2021 to 1 Jun 2021.
- 29 Aug 2017 Status changed from not yet recruiting to recruiting.